| P2093 | author name string | John S Bradley | |
| | Christopher M Rubino | |
| P2860 | cites work | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates | Q24244642 |
| | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis | Q24245058 |
| | Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis | Q30532136 |
| | Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. | Q33770046 |
| | Population pharmacokinetics of cefepime in the neonate | Q33883677 |
| | Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure | Q33938048 |
| | Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 |
| | Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 |
| | Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time | Q34069810 |
| | Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy | Q34131200 |
| | A multicenter evaluation of gentamicin therapy in the neonatal intensive care unit | Q34146978 |
| | Once daily dosing of gentamicin in infants and children | Q34461152 |
| | Once daily gentamicin dosing in neonates | Q77758812 |
| | Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates | Q79735915 |
| | Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia | Q34509676 |
| | Prospective determination of plasma imipenem concentrations in critically ill children. | Q34721638 |
| | Treatment of acute otitis media consensus recommendations | Q34776345 |
| | Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function | Q35013708 |
| | Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy | Q35140423 |
| | Clinical pharmacodynamics of quinolones | Q35623064 |
| | Antimicrobial treatment guidelines for acute bacterial rhinosinusitis | Q35630766 |
| | Population pharmacokinetic model for gatifloxacin in pediatric patients | Q35758967 |
| | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 |
| | High-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media | Q36047763 |
| | Treatment of streptococcal pharyngitis with once-daily compared with twice-daily amoxicillin: a noninferiority trial | Q36581282 |
| | Killing and regrowth of bacteria in vitro: a review. | Q37803210 |
| | A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients | Q40866399 |
| | Pharmacokinetics and pharmacodynamics of antibiotics in otitis media | Q41148314 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules | Q42537036 |
| | Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. | Q42631825 |
| | Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs | Q43580192 |
| | Pharmacokinetics of meropenem in preterm neonates | Q43612951 |
| | Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis | Q43789299 |
| | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing | Q44104691 |
| | "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy | Q44157139 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme | Q44692777 |
| | Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia | Q44873329 |
| | Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis | Q44905349 |
| | Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media | Q45054417 |
| | Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens | Q46476471 |
| | Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children | Q46525546 |
| | Pharmacodynamics of tobramycin in patients with cystic fibrosis | Q46554477 |
| | Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling | Q46731977 |
| | Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily | Q46971432 |
| | A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. | Q50509585 |
| | A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. | Q50509590 |
| | Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. | Q53882076 |
| | A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. | Q53982876 |
| | Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. | Q54147489 |
| | Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 |
| | Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon” | Q67729275 |
| | Gentamicin once-daily versus thrice-daily in children | Q72259506 |
| | Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children | Q73297667 |
| | Single daily dose of aminoglycosides--a concept whose time has not yet come | Q73322524 |
| | Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis | Q74528717 |
| | The pharmacodynamics of beta-lactams | Q74802265 |
| | The pharmacodynamics of aminoglycosides | Q74802269 |
| P433 | issue | 6 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 361-369 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics | |
| P478 | volume | 9 | |